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ABSTRACT 
Objective: The aim of the present study was to develop and evaluate buccal mucoadhesive tablets of ketorolac tromethamine.  
Methods: The tablets were prepared by direct compression using bioadhesive polymers such as carbobpl 934 with hydroxypropyl methylcellulose 
K4M and sodium carboxymethyl cellulose. The prepared tablets were characterized by different parameters such as weight uniformity, content 
uniformity, hardness, swelling index, in vitro drug release studies, ex- vivo residence time and ex- vivo permeation study.  
Results: F7 formulation containing Carbopol 934 and SCMC (at the ratio 1:3, respectively) showed good swelling, a convenient residence time as 
well as the highest amount of drug released within 6 hrs. Stability studies in natural saliva for 6 hrs, indicate that optimized F7 formulation has good 
stability in human saliva. In addition to the good correlation obtained between in vitro drug release and ex-vivo drug permeation study.  
Conclusion: The buccal mucoadhesive tablet of ketorolac could be an alternative route to reduce the pronounced gastrointestinal irritations, and 
reduce dosing frequency to improve patient compliance. 
Keywords: Ketorolac tromethamine, Adhesive buccal tablets, Mucoadhesive polymers.  
 
INTRODUCTION  
Mucoadhesive drug delivery system is now-a-days a booming field 
for research interest. These are delivery systems, which utilize the 
property of bioadhesion of certain polymers.  
Mucoadhesive buccal drug delivery systems offer many advantages 
over conventional systems such as ease of administration, be 
promptly terminated in case of toxicity by removing the dosage form 
from buccal cavity and it is also possible to administer drugs to 
patients who cannot be dosed orally via this route[1-2]. 
Recently much attention has been focused on the design and 
evaluation of buccal drug delivery systems keeping in view their 
potential for future market. Therefore a buccal drug delivery system 
needs to be developed and optimized. An ideal buccal adhesive 
system must have the following properties: should adhere to the site 
of attachment for few hours, should release the drug in controlled 
manner and should provide the drug release in a unidirectional way 
in the mucosa[3].  
The unique environment of the oral cavity offers its potential as a 
site for drug delivery. Through this route it is possible to realize 
mucosal (local effect) and transmucosal (systemic effect) drug 
administration. In the first case, the aim is to achieve a site-specific 
release of the drug on the mucosa, whereas the second case involves 
drug absorption through the mucosal barrier to reach the systemic 
circulation. Therapeutic agents administered through buccal mucosa 
enters directly to the systemic circulations and thereby circumvent 
the first pass hepatic metabolism, gastric irritation and other 
problems associated with conventional oral route[4-5].  
Ketorolac Tromethamine (KT) is a well known non-steroidal anti-
inflammatory drug with potent analgesic activity. Ketorolac is 
currently administered intramuscularly and orally in multiple 
divided doses for short-term management of post-operative pain[6]. 
The drug is administered via the oral route as a conventional tablet 
(10 mg four times a day) for management of mild to moderate pain 
[7]. In addition to the limitations in the available routes of 
administration, the half life of KT ranges from 4-6 h[6]. Therefore, 
frequent dosing is required to alleviate pain in postoperative 
patients due to its short half-life. To avoid an invasive drug delivery 
technique (i. e. intramuscular injection) and to decrease the 
gastrointestinal side effects produced by the oral tablets[8], there is 
a need for an alternative noninvasive mode of delivery for KT. The 
new delivery system should also provide sustain in the release of 
this medication to assist patient compliance. The buccal 
mucoadhesive administration may thus represent an alternative 
route for KT delivery. 
In the present investigation, an attempt was made to design 
efficacious and prolonged release mucoadhesive buccal tablets of 
ketorolac using various polymers to reduce dosing frequency, 
decrease gastric irritation and to improve patient compliance.  
MATERIALS AND METHODS  
Materials 
Ketorolac tromethamine (KT) was generously provided by Amirya 
Pharm. Ind. Co. (Alexandria, Egypt). Carbopol 934 (CP) (B. F., 
Goodrich Chemical Company, Ohio, USA), Hydroxypropyl 
methylcellulose (HPMC K4M); Biochemica, Switzerland, Sodium 
Carboxymethylcellulose (SCMC) (C. B. H. Lab Chemicals, Nottingham, 
U. K.), Polyvinyl pyrrolidone K30 (PVP k30): Sigma, USA. All other 
chemicals and solvents used were of pharmaceutical grade. 
Drug excipients compatibility study 
To investigate any possible interactions between the drug and the 
used bioadhesive polymers, infrared spectroscopy (IR) was adopted. 
The IR spectrum of a) pure ketorolac, b) physical mixture containing 
drug, CP 934 and HPMC K4M c) physical mixture containing drug, CP 
934 and SCMC were taken, interpreted and compared with each 
other. The IR spectra were carried out using Shimadzu IR-470 
spectrophotometer (Tokyo, Japan). The samples were prepared as 
KBr disks compressed under a pressure of 6 tones/cm2. The 
scanning range was 400-4000 cm-1. 
Preparation of Mucoadhesive Buccal Tablets  
Mucoadhesive buccal tablets each containing 10 mg ketorolac were 
prepared by direct compression method. Composition of various 
formulations employing carbopol 934, SCMC and HPMC are shown 
in table (1) was mixed homogeneously in a glass mortar for 15 
minutes. The mixture (100 mg) is compressed using 7 mm flat faced 
punch on 16 stages rotary tablet compress machine. 
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14 6 - 35 35 10  F1 
14 6 - 46 23 10 F2 
14 6 - 54 18 10  F3 
14 6 - 56 14 10  F4 
14 6 35 - 35 10  F5 
14 6 46 - 23 10  F6 
14 6 54 - 18 10  F7 
14 6 56 - 14 10  F8 
 
Surface pH  
The surface pH of the buccal tablets was determined in order to 
investigate the possibility of any side effects in vivo. As an acidic or 
alkaline pH may cause irritation to the buccal mucosa, it was 
determined to keep the surface pH as close to neutral as possible. 
The tablet was allowed to swell by keeping it in contact with 1 mL of 
distilled water (pH 6.5 ± 0.05) for 2 hours at room temperature. The 
pH was measured by bringing the electrode in contact with the 
surface of the tablet and allowing it to equilibrate for 1 minute[9]. 
Swelling index 
Buccal tablets were weighed individually (Wo) and placed separately 
in 2% agar gel plates and incubated at 37oC ±1oC. At regular 1-hour 
time intervals until 6 hours, the tablet was removed from the Petri 
dish, and excess surface water was removed carefully with filter 
paper. The swollen tablet was then reweighed (W1) and the swelling 
index (S. I) was calculated using the formula[10] given in Equation 1.  
Swelling index = 100 (W1 -Wo) / Wo ……. (1) 
Drug content 
Five tablets were taken and powdered; powder equivalent to one 
tablet was taken and dissolved in 100 ml of pH 6.8±0.5 phosphate 
buffer on a rotary shaker overnight. The solution was centrifuged 
and the supernatant was collected[11]. The absorbance was 
measured by using UV-visible spectrophotometer at 322 nm. Each 
measurement was carried out in triplicate and the average drug 
content in the buccal tablet was calculated. 
In vitro drug release 
The drug release rate from buccal tablets was studied using the USP 
type II dissolution test apparatus. The dissolution medium consisted 
of 200 ml of phosphate buffer pH 6.8 ±0.5. The release was 
performed at 37oC ± 0.5oC, with a rotation speed of 50 rpm. The 
tablet was supposed to release drug from one side only hence a one 
side of tablet was fixed to glass disk with cyanoacrylate adhesive. 
The disk was placed at the bottom of the dissolution vessel. Samples 
(3 mL) were withdrawn at predetermined time intervals and 
replaced with fresh medium[12]. The samples were filtered through 
filter paper and analyzed by UV spectrophotometer at 322 nm.  
Release data were fitted to various mathematical models 
Korsmeyer-Peppa’s [13], zero order, first order and Higuchi release 
models [14] in order to determine the release mechanism. 
Ex-vivo mucoadhesion time 
The ex-vivo mucoadhesion time was performed (n = 3) after 
application of the buccal tablet on freshly cut sheep buccal mucosa. 
A segment of fresh sheep buccal mucosa (2 cm) was glued to the 
surface of glass slide, and a mucoadhesive buccal tablet was wetted 
with 1 drop of phosphate buffer pH 6.8±0.5 and pasted to the sheep 
buccal mucosa by applying a light force with a fingertip for 30 
seconds. The glass slide was then put in the beaker, which was filled 
with 100 mL of the phosphate buffer pH 6.8, and was kept at 37oC ± 
1oC. After 2 minutes, a 50-rpm stirring rate was applied to simulate 
the buccal cavity environment, and tablet adhesion was monitored 
for 8 hours. The time for the tablet to detach from the sheep buccal 
mucosa was recorded as the mucoadhesion time[15].  
Ex- vivo drug permeation 
The ex-vvo buccal permeation studies was carried out for optimized 
ketorolac buccal tablet. The permeation study of ketorolac through 
the excised layer of goat buccal mucosa was performed using Franz 
diffusion cell at 37oC ± 0.5oC. Fresh goat buccal mucosa was mounted 
between the donor and receptor compartments. The buccal tablet 
was placed with the core facing the mucosa, and the compartments 
were clamped together. The donor compartment was filled with 1 
m1 of phosphate buffer pH 6.8. The receptor compartment (45 ml 
capacity) was filled with phosphate buffer pH 6.8 ± 0.5and the 
hydrodynamics in the compartment was maintained by stirring with 
a magnetic bead at uniform slow speed[16]. The amount of drug 
permeated through the buccal mucosa was determined by 
withdrawing samples (1 ml) at predetermined time intervals and 
analyzed for drug content by UV spectrophotometer at 322 nm. 
RESULTS AND DISCUSSION  
FTIR studies revealed that, no interaction between the drug and the 
used polymers occurred as there was no shift in the IR peaks of the 
drug (Figure 1).  
The physico-chemical characteristics of Ketorolac muacoadhesive 
buccal tablets are shown in Table 2. All the tablet formulations 
showed almost uniform weight, thickness and favorable hardness. 
The weight of the tablets was varied between 107.7 mg and 96.6 mg 
with SD values 0.4 - 0.8. The thicknesses of the various tablet 
formulations were observed to be in the range of 2.6 mm to 3.64 mm 
with SD values of 0.06-0.28.  
 
 
Fig. 1: a) pure ketorolac b) physical mixture of ketorolac, 
carbopol 934 and HPMC c) physical mixture of ketorolac, 
carbopol 934 and SCMC 
 
The hardness of all the tablets was found to be in the range of 3.7 to 
4.8 kg/cm2. The average drug content of the tablets was found to be 
within the range of 95.35% to 101.41% and the low values of 
standard deviation indicate uniform distribution of the drug within 
the prepared mucoadhesive buccal tablets. The surface pH of all the 
tablets was within a range of 6.4 to 7.1 (Table 2), which was close to 
neutral pH. Hence, it is assumed that these formulations cause no 
irritation in the oral cavity.  
 
 
The swelling profile of different buccal tablets is shown in figures 2 
and 3. The results of swelling study revealed that the swelling index 
of all tablets was increased by time because the polymers gradually 
absorb water due to hydrophilicity of the polymers. The swelling 
state of the polymer (in the formulation) was reported to be crucial 
for its bioadhesive behavior. Appropriate swelling behavior of 
mucoadhesive buccal system is an essential property for uniform 
and prolonged drug release and effective mucoadhesion. The 
adhesion will increase with the degree of hydration until a point 
where over-hydration leads to an abrupt drop in adhesive strength 
due to disentanglement at the polymer/tissue interface[17]. The 
swelling index was directly proportional to the concentration of the 
second polymer (HPMC or SCMC) and inversely proportional to 
CP934. The higher swelling rate and extent of buccal tablets 
containing SCMC can be explained due to the faster rate of water 
uptake by SCMC than by HPMC. 
Table 2: Physicochemical properties of Ketorolac Tromethamine mucoadhesive buccal tablets 





> 8 95.3 ± 0. 21 6.4 ± 0.05 3.9±0.11 2.6±0.08 106.5±0.5 F1 
> 8 97.2 ± 0.28 6.8 ± 0.1 3.9±0.17 3.64±0.12 96.6±0.52 F2 
> 8 96.7 ± 0.46 6.9 ±0.05 3.8±0.1 2.63±0.22 99.6±0.4 F3 
5.30 ± 0.5 95.5 ± 0.51 7.02 ±0.15 3.7±0.25 2.99±0.1 104.8±0.8 F4 
> 8 98.6 ± 0.35 6.6 ±0.05 3.8±0.15 3.62±0.11 101.3±0.57 F5 
5.5 ± 1.05 98.7 ± 0.2 6.9 ±0.05 4.1±0.15 3.26±0.13 99.2±0.33 F6 
6. 5 ± 0.5 99.1 ± 0.32 7 ± 0.1 4. 8 ±0.21 3.36±0.06 107.7±0.45 F7 
5 ± 0.7 101.4 ± 0.25 7.1 ± 0.1 4.6±0.21 2.6±0.28 100.6±0.5 F8 
 
The swelling index after 6 hrs was in the range from 16.94% to 
42.18% for buccal tablets containing CP 934 with HPMC (F1-F4), 
while for buccal tablets containing CP934 with SCMC (F5-F8) was in 
the range from 32.59% to 52.3%. Buccal tablets containing Cp934 
and SCMC at the ratios of 1:2 and 1:3 exhibited the highest swelling 
(48.5 % and 52.3%, respectively).  
 
Fig. 2: Swelling study of Ketorolac tromethamine buccal tablets 
containing different ratios of carbopol 934and HPMC 
 
 
Fig. 3: Swelling study of Ketorolac tromethamine mucoadhesive 
buccal tablets containing different ratios of carbopol 934and 
SCMC 
 
A putative and effective mucoadhesive formulation should not only 
be able to adhere to the mucosal surface, but also be capable of 
remaining in place for an extended period of time. Hence, assessing 
the duration of mucoadhesion of buccal tablets is critical [18]. The 
polymeric materials become adhesive with hydration while 
excessive swelling leads to reduced mucoadhesiveness because 
water molecules bind to polymer groups required for adhesion[19]. 
Ex vivo mucoadhesion time for the prepared buccal tablets (F1 to 
F8) varied from 5 to more than 8 hours (Table 2). The difference 
between the values of the ex-vivo mucoadhesion time for buccal 
tablets could be attributed to the combination of various amounts of 
the polymers, which affected the mucoadhesion. Moreover, SCMC, 
owing to its solubility in water and the observed higher swelling rate 
and extent, resulted in lower mucoadhesion time. In fact, with buccal 
tablets containing a higher proportion of CP, mucoadhesion time 
was found to be increased. 
In vitro drug release studies revealed that the release of ketorolac 
from different formulations varies with characteristics and 
composition of matrix forming polymers as shown in figure 4 and 5. 
The drug release rate appeared to increase with decreasing carbopol 
934 and increasing concentration of SCMC and HPMC. The gradual 
swelling of buccal tablets containing CP 934 and SCMC inevitably 
facilitated the release of ketorolac due to easier diffusion in the 
swelled region of the polymer network. The prolonged release of 
drug from buccal tablets containing higher percentages of CP 934 
may be explained by its properties of in situ gelling and slow 
dissolution.  
Therefore increase of carbopol content delays the drug release from 
tablets. The in vitro drug release of formulations F1 to F4 
(containing CP 934 and HPMC at different ratios) was found to be in 
the range of 44.6% ± 1.5 to 63.93% ± 1.07. On the other hand 
formulations F5 to F8 (containing CP 934and SCMC at different 
ratios) was found to be in the range of 77.55% ± 2.06 to 100.1% ± 
1.85. This finding was also supported by the results of swelling 
studies where the highest swelling index was also exhibited by the 
formulation containing SCMC and CP 934 (Fig. 3). It is anticipated 
that the high amount of water uptake by SCMC may leads to 
considerable swelling of the polymer matrix, allowing the drug to 
diffuse out at a faster rate. 
Among the formulation studied F7 and F8 (containing CP 934and 
SCMC at ratios 1:3 and 1:4, respectively) showed the highest amount 
of drug released within 6 hours (100% and 98%, respectively). 
Kinetics of drug release and mechanism 
The obtained values of n (diffusional exponent), and r2 
(correlation coefficient) are depicted in table 3. The values of n are 
estimated by linear regression of log (Mt/M∞) versus log (t), and 
these values were between 0.5 and 1.0, indicating that the release 
of ketorolac was found to be a non-Fickian diffusion. The only 
exception was formulation F2, as the ‘n’ value of formulation F2 is 
closer to 0.5, the drug release mechanism from this formulation is 
Fickian diffusion.  
The order of drug release from all the formulations was studied, and 
it followed zero-order kinetics 
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Fig. 4: In vitro drug release study of Ketorolac tromethamine 
mucoadhesive buccal tablets containing CP934 with HPMC 
 
 
Fig. 5: In vitro drug release study of Ketorolac tromethamine 
buccal tablets containing CP 934 with SCMC 
 
Table 3: Drug release kinetics studies of ketotolac tromethamine buccal tablets 










F1 0.941 0.8351 0.868 0.752 0.972 0.81 
F2 0.9291 0.884 0.929 0.869 0.9391 0.47 
F3 0.9940 0.992 0.926 0.826 0.965 0.674 
F4 0.8044 0.733 0.86 0.772 0.923 0.671 
F5 0.934 0.923 0.825 0.698 0.971 0.962 
F6 0.99 0.92 0.925 0.86 0.948 0.971 
F7 0.965 0.957 0.922 0.828 0.964 0.975 
F8 0.978 0.970 0.865 0.735 0.946 0.999 
 
On the basis of above result F7 formulation was selected for ex vivo 
drug permeation studies. The results of drug permeation from 
buccal tablets through the sheep buccal mucosa showed 53.16% ± 
2.02% (Fig. 6) drug permeated during 6 hours. Good correlation was 
obtained between in vitro drug release and ex-vivo drug permeation 
study with the correlation coefficient of 0.974. The stability of 
mucoadhesive buccal tablets was examined in natural human saliva. 
The obtained data are presented in Table 4. Buccal tablets did not 
exhibit change in color or shape. Physical properties of the buccal 
tablets such as diameter increased slightly owing to swelling of the 
buccal tablets in human saliva. But the buccal tablets did not collapse 
in the human saliva until the end of the study. No change in drug 
content was observed over the period of 6 hours in human saliva, 
the drug content was in the range of 97 % to 99.2%. 
Table 4: Stability study of the selected F7 ketorolac buccal tablet formulation in normal human saliva 
Sampling 
Time (hours) 
























*Visual observation **Mean of three readings 
 
Fig. 6: Drug permeation % of the selected F7 formulation 
CONCLUSION 
It was concluded that development of muoadhesive buccal tablets of 
ketorolac was one of the alternative routes of administration to 
avoid gastrointestinal irritation as it is the most pronounced adverse 
effects associated with its use. In addition, these formulations reduce 
the need of frequent administration and enhance patient 
compliance. F7 formulation containing Carbopol 934 and SCMC (at 
the ratio 1:3, respectively) showed good swelling, a convenient 
residence time as well as promising drug release pattern. In addition 
to the good correlation obtained between in vitro drug release and ex-
vivo drug permeation study with the correlation coefficient of 0.974.  
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